Press Releases

Alloy Therapeutics, a biotechnology ecosystem company, announced it has acquired deepCDR Biologics, a Basel, Switzerland-based developer of deep learning technology for antibody discovery and optimization. The team and technology stack will form new bioinformatics and machine learning (ML) capabilities for Alloy and will be fully integrated into Alloy Discovery Services complementary workflow and processes. Alloy will expand the Basel deepCDR site as a permanent Alloy research facility and wi

Gedeon Richter Plc. ("Richter") and Hikma Pharmaceuticals PLC ("Hikma") today announced that they have entered into an exclusive license agreement to commercialise Richter's denosumab, comprising two biosimilar products referencing Prolia® and Xgeva® ("Products"), in the United States ("US"). The Products are used for the treatment of osteoporosis and fractures due to bone metastasis respectively and are currently in global Phase 1 and Phase

SRI Biosciences has been awarded a $14.7 million contract sponsored by the Defense Threat Reduction Agency (DTRA) through the Medical, Chemical, Biological, Radiological, and Nuclear Defense Consortium (MCDC) to continue development of a high-concentration naloxone product for intravenous, intramuscular and subcutaneous injection, or intravenous infusion. Under the three-year contract, SRI will advance their in-development naloxone product from an Investigational New Drug (IND) appl

PharmaCyte Biotech, Inc., a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the results of an additional, more detailed, analysis of the integration site of the cytochrome P450 2B1 gene from the augmented HEK293 cell clone that PharmaCyte uses in its CypCap™ product. This assay is one of the assays required by the U.S. Food and Drug Administration (FDA) in o

Xcovery Holdings, Inc., an oncology focused bio-pharmaceutical company, is proud to announce the acquisition of a majority and controlling stake in Meryx Inc., a clinical stage immuno-oncology company based in Chapel Hill, North Carolina developing TKIs in a range of hematologic and solid malignancies, including lung cancer. The partnership and synergies between Xcovery and Meryx will accelerate and enhance both Xcovery’s and Meryx's missions to develop small molecule oncology drugs

Roquette, a global leader in plant-based ingredients and a leading provider of naturally-derived pharmaceutical excipients, today announces its plans to open a new Innovation Center in the US to further the advancement of prescription drugs – and beyond. Located in Pennsylvania, the new state-of-the-art facility aims to better serve Roquette’s global customer base by working closely with its specialist pharmaceutical teams, based at sister sites in Singapore and France. Together,

The Melanoma Research Alliance (MRA), the largest non-profit funder of melanoma research worldwide, welcomes the U.S. Food and Drug Administration (FDA) decision to expand eligibility of Merck’s Keytruda (pembrolizumab) to include patients with Stage IIB and IIC melanoma. Melanoma, the deadliest skin cancer, is the fifth most common cancer in the U.S. While surgery is curative for most patients with early-stage disease, an estimated 27% percent of patients with Stage II melano

ASLAN Pharmaceuticals, a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the appointment of IQVIA Biotech, a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, as its preferred clinical research organization for logistics related to decentralized clinical trials, including the global oversight, expansion and engagemen

Leading pharma-packaging firm, KAISHA Packaging, has accomplished new heights in the fight against COVID-19. The company has successfully provided over 2 billion doses worth of flip-top aluminium seals used for packaging COVID vaccines. The seal is used as closures for injection vials during the vaccination drive and is as such an essential part of the vaccine package ensuring tamper-proof delivery.  This is especially relevant for fulfilling India and the world’s current vaccinati

Kolon TissueGene, Inc., a leader in advanced cell and gene therapies, announced today that the FDA has allowed the Company to proceed with initiation of a Phase II clinical trial in osteoarthritis (OA) of the hip. Kolon TissueGene has begun activities to initiate the Phase II trial. The Phase II, multicenter, randomized, double-blind, placebo-controlled trial will enroll about 255 patients at over 25 clinical sites across the United States. During the trial, the company will assess